隶属于 强生
相关临床试验
13
2 进行中
药物批准
33
批准总数
监管机构
2
监管机构数
成立时间
1979
进行中（未招募）
2
15.4%
Approved For Marketing
1
7.7%
已完成
8
61.5%
终止
2
15.4%
- Final Phase 3 PAPILLON data show first-line RYBREVANT plus carboplatin-pemetrexed achieved median overall survival of 34.3 months versus 27.9 months with chemotherapy alone in EGFR exon 20 insertion NSCLC. - A prespecified crossover-adjusted analysis showed a significant survival benefit, reducing the risk of death by 43 percent (HR 0.57; 95% CI 0.39-0.82; nominal P=0.003). - The combination extended progression-free survival through second disease progression by more than 10 months (28.3 vs 17.5 months; HR 0.59; nominal P<0.0001). - Results were presented at the IASLC 2026 World Conference on Lung Cancer and represent the longest reported median overall survival in this historically poor-prognosis population.
- The Health Resources and Services Administration has approved eight pharmaceutical companies to participate in the 340B Rebate Model Pilot Program, which will begin on January 1, 2025. - Nine drugs from major manufacturers including Bristol Myers Squibb's Eliquis, Novo Nordisk's Novolog, and Janssen's Stelara will be included in the voluntary rebate program. - The pilot program allows drugmakers to provide 340B discounted pricing through a rebate model rather than upfront discounts, with HRSA planning to evaluate the program for at least one year. - The initiative follows legal challenges from Johnson & Johnson, Bristol Myers Squibb, and Eli Lilly regarding HRSA's authority to review and approve rebate models in the 340B program.
- Phase 3 trials show Icotrokinra significantly improved skin clearance in adults and adolescents with moderate to severe plaque psoriasis. - At week 16, 64.7% of patients achieved clear or almost clear skin (IGA 0/1) with Icotrokinra, compared to 8.3% on placebo. - Icotrokinra, a once-daily oral peptide selectively blocking the IL-23 receptor, demonstrated a safety profile consistent with earlier studies. - Further improvements were seen at week 24, with 74.1% achieving IGA 0/1 and 64.9% achieving PASI 90, highlighting sustained efficacy.
- Johnson & Johnson has submitted applications to the FDA and EMA for Darzalex Faspro to treat high-risk smoldering multiple myeloma. - The applications are based on Phase 3 AQUILA study data, which evaluated Darzalex Faspro as a monotherapy in adult patients. - Smoldering multiple myeloma is an early precursor to active multiple myeloma, with a high risk of progression in some patients. - Darzalex, a CD38-directed antibody, could potentially become the first approved treatment for this high-risk patient population.
